Entities / Company
Repligen.
bioTech Company
- Reports this week
- 0
- Active events
- 0
- Connections
- 54
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
-
Repligen and Sonic Healthcare are identified as competing healthcare companies in the market.Some support1 report
-
Repligen is investing in dual manufacturing in Europe while simultaneously increasing its presence in the APAC region.Some support1 report
-
Benchmark upgraded Repligen rating to buy, while Jefferies Financial Group reaffirmed a hold rating on the company.Some support1 report
Gone quiet
No new reports in 90+ days-
Shareholders are seeking increased consideration for a sale, while an investor rights firm investigates potential breaches involving several companies.Some support1 report
-
Repligen opened a new Training & Innovation Center in Breda.Some support1 report
-
Repligen operates in North America and internationally.Some support1 report
-
China saw some pull-forward demand for Repligen in August 2025.Some support1 report
-
Market trends indicate that small biotech sales are softening due to weak funding, amidst discussions about robust order momentum in biopharma manufacturing.Speculative1 report
-
General negative market sentiment weighed on the biotech and pharmaceutical sectors in late July 2025.Some support9 reports2 developments inside
-
Repligen, along with other biopharmaceutical companies, is involved in providing bioprocessing technologies and solutions for the industry.Some support1 report
-
Repligen and Medpace were cited alongside Monster Beverage and Microsoft as thematic investing winners in the drug development inputs segment.Some support3 reports
-
Repligen's company performance was boosted by strong biopharma demand and revenue from consumables and capital equipment.Some support1 report
-
Repligen announced a partnership with Novasign to integrate Novasign's ML into its systems and invest in its operations.Some support1 report
-
Repligen Corporation is based in Waltham, MA.Some support1 report
-
Chuck Royce, portfolio manager of Royce Pennsylvania Mutual Fund, increased his stake in certain companies.Some support1 report
-
A market rally fueled by positive inflation data involved several companies, including Acadia Healthcare, NeoGenomics, BrightSpring, and Repligen.Some support1 report1 development inside
-
Repligen and Li Auto reported that their revenue growth outpaced U.S. market growth on August 15, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Repligen this week
News at the entities that move Repligen most-
Jim Cramer OperationalFed rate hikes trigger market sell-offs, prompting Jim Cramer to advise selling while Elon Musk enters the telecom sector.Moves Repligen
-
Benchmark Mentioned togetherBenchmark lifted its price objective and gave a buy rating for Amazon.com.Moves Repligen
-
Europe OperationalHill and Carl Cannon offer critiques and alternatives regarding European welfare state and economic issues.Moves Repligen
-
Jefferies Financial Group Mentioned togetherJefferies Financial Group initiated coverage on Moody's shares, and Morgan Stanley subsequently raised its price target for the company.Moves Repligen
-
North America Shared contextAlign Technology reported mixed regional performance, with flat sales in North America but double-digit volume growth in APAC and Latin America.Moves Repligen
-
Ireland Shared contextA documentary about Ireland's population was fronted, and individuals gave interviews to the Irish Independent.Moves Repligen
Connections
The 14 strongest of 54, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
BIOLIFE Transactional
Repligen is completing the acquisition of BioLife through a merger, integrating its cell processing tools and services business.
-
Jim Cramer Operational
Jim Cramer actively highlights and recommends Repligen as a top-performing stock.
-
Benchmark Mentioned together
Benchmark provided a rating upgrade on Repligen, indicating market coverage and analysis.
-
Breda Shared context
Repligen established a Training & Innovation Center in the city of Breda.
-
Europe Operational
Repligen is actively investing in dual manufacturing facilities within the European market to support its operational strategy.
-
Sonic Healthcare Operational
Both Repligen and Sonic Healthcare are identified as competing companies within the healthcare market.
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group provides market analysis and ratings for Repligen.
-
North America Shared context
Repligen operates within North America as part of its international business presence.
Show all 14 connections
-
Apac Shared context
Repligen is expanding its presence in the APAC region to address market demand.
-
Ireland Shared context
Repligen maintains manufacturing sites within Ireland.
-
BioPharma Mentioned together
Both entities are mentioned in the context of general market trends and funding within the biopharma sector.
-
Sweden Shared context
Repligen maintains manufacturing sites within Sweden.
-
Estonia Shared context
Repligen operates and maintains manufacturing sites within Estonia.
-
Netherlands Shared context
Repligen maintains manufacturing sites within the Netherlands.
History
Events by the month they beganAugust 2026
3 events- Repligen and Sonic Healthcare are identified as competing healthcare companies in the market.
- Repligen is investing in dual manufacturing in Europe while simultaneously increasing its presence in the APAC region.
- Benchmark upgraded Repligen rating to buy, while Jefferies Financial Group reaffirmed a hold rating on the company.
July 2026
4 events- Repligen is acquiring BioLife Solutions, which supplies cell processing tools and services.
- Shareholders are seeking increased consideration for a sale, while an investor rights firm investigates potential breaches involving several companies.
- Repligen opened a new Training & Innovation Center in Breda.
- Repligen operates in North America and internationally.
June 2026
12 events- Repligen has manufacturing sites in Estonia, Ireland, Netherlands, and Sweden, and is attending conferences in Boston and London.
- China saw some pull-forward demand for Repligen in August 2025.
- Market trends indicate that small biotech sales are softening due to weak funding, amidst discussions about robust order momentum in biopharma manufacturing.
- General negative market sentiment weighed on the biotech and pharmaceutical sectors in late July 2025.
- Repligen, along with other biopharmaceutical companies, is involved in providing bioprocessing technologies and solutions for the industry.
- Repligen and Medpace were cited alongside Monster Beverage and Microsoft as thematic investing winners in the drug development inputs segment.
- Repligen's company performance was boosted by strong biopharma demand and revenue from consumables and capital equipment.
- Repligen announced a partnership with Novasign to integrate Novasign's ML into its systems and invest in its operations.
- Repligen Corporation is based in Waltham, MA.
- Chuck Royce, portfolio manager of Royce Pennsylvania Mutual Fund, increased his stake in certain companies.
- A market rally fueled by positive inflation data involved several companies, including Acadia Healthcare, NeoGenomics, BrightSpring, and Repligen.
- Repligen and Li Auto reported that their revenue growth outpaced U.S. market growth on August 15, 2025.